Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ONCY · NASDAQ · Pharmaceutical Preparations
Oncolytics Biotech (ONCY) · oqro.io/stocks/ONCY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.37−0.002 (−0.54%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
−65.7% (−$0.71) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.08 on Nov 13, 2025 to $0.37 on Nov 13, 2026 (−65.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Diego, Ca.
Last 12 months
−65.7%
Market value
$47.2M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.68M shares sold short (6.8% of shares outstanding), −3.8% vs the previous count, 9.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$8.14M
This quarter −$8.14M, a year earlier −$4.11M
Net debt
—
Debt —, cash $4.12M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Oncolytics Biotech is on record in SEC filings since 2006.
No open-market sale by an insider of Oncolytics Biotech (ONCY) was filed with the SEC in the last 90 days.
No trade in Oncolytics Biotech (ONCY) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
0 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in breast cancer metastatic, anal cancer metastatic, ras-mutated metastatic colorectal cancer. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Notice of delisting or failure to meet listing rules
8-K on sec.govChanged auditor
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Against the S&P 500 over the year
Since Nov 12, 2025, ONCY is down 67.4% and the index fund is up 10.4%: 78 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ONCY moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
On the public record for Oncolytics Biotech over the 12 months to Nov 14, 2026: 2 clinical trials.
